For SLX-100, we will be referencing safety and dosing from previously published studies not conducted by Solaxa in our 505b2 expedited regulatory submission
Issued patent protection
through 2036: 4-Aminopyridine
through 2038: Confidential
5 issued (US, EU & Canada) and 8 pending / provisional patents exclusively licensed
